EGFR and non-small cell lung carcinoma: EGFR TKIs of the first- or second-generation, such as gefitinib, erlotinib, afatinib, icotinib, and dacomitinib, demonstrated higher overall response rate (ORR) and longer progression-free survival (PFS) compared with chemotherapy and are therefore standard first-line treatments for EGFR-positive NSCLC [1,3].